Stem Cell Therapy for Liver Transplant Complications

This trial examines the safety of a special type of stem cell therapy for individuals with severe liver disease undergoing a liver transplant from a living donor. The goal is to determine if these stem cells, derived from a person's own fat (autologous adipose-derived mesenchymal stem cells), can enhance the surgery process and recovery. This study targets individuals scheduled for a living donor liver transplant who do not have other major health issues, such as active infections or very high body weight. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial information does not specify whether you need to stop taking your current medications. However, if you are taking any investigational drugs or using investigational devices, you must stop at least 60 days before joining the study.

Research has shown that using a person's own fat-derived stem cells may improve liver health. These cells can reduce liver scars and help restore liver function. However, some clinical trials have reported side effects, with blood clots and liver scarring being the most common.

Researchers are excited about using autologous adipose-derived mesenchymal stem cells for liver transplant complications because these stem cells have the unique ability to repair and regenerate damaged liver tissues. Unlike traditional immunosuppressive drugs and supportive care, which primarily manage symptoms and prevent rejection, these stem cells work by promoting healing directly at the cellular level. This approach not only has the potential to improve liver function more effectively but may also reduce the need for long-term medication, minimizing side effects and enhancing overall recovery.

Research has shown that certain stem cells, such as those from fat tissue, may help treat liver issues. Studies have found that these stem cells can improve liver health, reduce scarring, and enhance liver function. A review of several studies found that stem cell therapy can significantly increase survival rates and improve outcomes for people with liver failure. Early research also suggests that similar treatments have helped improve liver function in people with liver cirrhosis, which involves scarring of the liver. This trial will investigate the use of autologous adipose-derived mesenchymal stem cells in liver transplant patients, aiming to potentially reduce complications and improve liver health.¹²⁶⁷⁸